Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Sponsored by Revance Therapeutics, Inc.
About this trial
Last updated 11 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Ended 16 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Female or male, 30 to 60 years of age
- Bilateral lateral canthal lines rated as moderate or severe
- Willing to refrain from receiving facial fillers, laser treatments, use of any product that affects skin remodeling or a product that may cause an active dermal response in the treatment area beginning at Screening and through End of Study
- Women of childbearing potential must be practicing and willing to continue to use an effective method of birth control during the course of the study
Exclusion Criteria
- Muscle weakness or paralysis in the area receiving study treatment -Active skin disease or irritation at the treatment areas
- Undergone any procedures that may affect the lateral canthal region during the past 12 months prior to Screening
- Use of a topical steroid on either of the treatment areas or use of medications that suppress the immune system 30 days prior to Screening and continuing through End of Study (Day 28)
- Any abnormality on the electrocardiogram (ECG) at Screening or any history of clinically significant arrhythmia, unstable angina, myocardial infarction or congestive heart failure.
- Previous treatment with Botulinum Toxin Type A in the face area